Collection 5 (Sep 2024 - Aug 2025) Articles

Articles
Triple Assessments of Atherosclerosis in Patients With Heterozygous Familial Hypercholesterolemia
Tada H, Kojima N, Yamagami K, et al.
Journal:
JACC Asia

First published: June 18, 2025 DOI: 10.1016/j.jacasi.2025.04.011
View
- Share
Articles
Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a)
Wulff AB, Nordestgaard BG
Journal:
Eur Heart J

First published: June 16, 2025 DOI: 10.1093/eurheartj/ehaf274
View
- Share
Articles
Colchicine for Secondary Prevention in Established ASCVD: A Systematic Review and Meta-Analysis
Abdelaziz A, Sobhy A, Nazmy A, et al.
Journal:
Eur J Prev Cardiol

First published: June 12, 2025 DOI: 10.1093/eurjpc/zwaf332
View
- Share
Articles
Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline: What It Is and What It Might Have Been
Brandts J, Ray KK
Journal:
J Am Coll Cardiol

First published: June 10, 2025 DOI: 10.1016/j.jacc.2025.04.024
View
- Share
Articles
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis
Fukami H, Oike Y
Journal:
J Atheroscler Thromb

First published: June 5, 2025 DOI: 10.5551/jat.RV22038
View
- Share
Articles
Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies
Barkas F, Brandts J, De Bacquer D, et al.
Journal:
J Am Coll Cardiol

First published: June 3, 2025 DOI: 10.1016/j.jacc.2025.04.010
View
- Share
Articles
Comparison of coronary artery calcification in breast cancer survivors with age matched controls: A prospective case-control study
Sreevatsa A, Sreedhara Rao Nadig S
Journal:
J Clin Oncol

First published: May 28, 2025 DOI: 10.1200/JCO.2025.43.16_suppl.e24017
View
- Share
Articles
Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia
Landmesser U, Laufs U, Schatz U, et al.
Journal:
Am Heart J

First published: May 26, 2025 DOI: 10.1016/j.ahj.2025.05.014
View
- Share
Articles
Estimating the Global Impact of Lp(a) Across Different Thresholds and Populations: Challenges for Personalized Risk Prediction
Blankstein R, Berman A, Shiyovich A, et al.
Journal:
JACC

First published: May 26, 2025 DOI: 10.1016/j.jacc.2025.04.032
View
- Share
Articles
Lipoprotein(a) and High-Risk Coronary Plaque: Dawn of a New Era in Assessment and Management of Vulnerable Plaque
Wee S, Ahn J, Kang D, et al.
Journal:
JACC

First published: May 26, 2025 DOI: 10.1016/j.jacc.2025.04.029
View
- Share
Articles
Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques: A PROSPECT II Substudy
Erlinge D, Tsimikas S, Maeng M, et al.
Journal:
JACC

First published: May 26, 2025 DOI: 10.1016/j.jacc.2025.04.013
View
- Share
Articles
The aspirin heart disease prevention conundrum
Superko HR, Sninsky J, Garrett B
Journal:
Am J Prev Cardiol

First published: May 21, 2025 DOI: 10.1016/j.ajpc.2025.101013
View
- Share

1 2 3 4 5 … 10

Collection 5 (Sep 2024 - Aug 2025) Articles

Articles

Triple Assessments of Atherosclerosis in Patients With Heterozygous Familial Hypercholesterolemia

Tada H, Kojima N, Yamagami K, et al.

Articles

Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a)

Wulff AB, Nordestgaard BG

Articles

Colchicine for Secondary Prevention in Established ASCVD: A Systematic Review and Meta-Analysis

Abdelaziz A, Sobhy A, Nazmy A, et al.

Articles

Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline: What It Is and What It Might Have Been

Brandts J, Ray KK

Articles

ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis

Fukami H, Oike Y

Articles

Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies

Barkas F, Brandts J, De Bacquer D, et al.

Articles

Comparison of coronary artery calcification in breast cancer survivors with age matched controls: A prospective case-control study

Sreevatsa A, Sreedhara Rao Nadig S

Articles

Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia

Landmesser U, Laufs U, Schatz U, et al.

Articles

Estimating the Global Impact of Lp(a) Across Different Thresholds and Populations: Challenges for Personalized Risk Prediction

Blankstein R, Berman A, Shiyovich A, et al.

Articles

Lipoprotein(a) and High-Risk Coronary Plaque: Dawn of a New Era in Assessment and Management of Vulnerable Plaque

Wee S, Ahn J, Kang D, et al.

Articles

Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques: A PROSPECT II Substudy

Erlinge D, Tsimikas S, Maeng M, et al.

Articles

The aspirin heart disease prevention conundrum

Superko HR, Sninsky J, Garrett B

Articles

Triple Assessments of Atherosclerosis in Patients With Heterozygous Familial Hypercholesterolemia

Tada H, Kojima N, Yamagami K, et al.

Share

Articles

Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a)

Wulff AB, Nordestgaard BG

Share

Articles

Colchicine for Secondary Prevention in Established ASCVD: A Systematic Review and Meta-Analysis

Abdelaziz A, Sobhy A, Nazmy A, et al.

Share

Articles

Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline: What It Is and What It Might Have Been

Brandts J, Ray KK

Share

Articles

ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis

Fukami H, Oike Y

Share

Articles

Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies

Barkas F, Brandts J, De Bacquer D, et al.

Share

Articles

Comparison of coronary artery calcification in breast cancer survivors with age matched controls: A prospective case-control study

Sreevatsa A, Sreedhara Rao Nadig S

Share

Articles

Design and rationale of the VICTORION-Difference study: A phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran’s early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia

Landmesser U, Laufs U, Schatz U, et al.

Share

Articles

Estimating the Global Impact of Lp(a) Across Different Thresholds and Populations: Challenges for Personalized Risk Prediction

Blankstein R, Berman A, Shiyovich A, et al.

Share

Articles

Lipoprotein(a) and High-Risk Coronary Plaque: Dawn of a New Era in Assessment and Management of Vulnerable Plaque

Wee S, Ahn J, Kang D, et al.

Share

Articles

Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques: A PROSPECT II Substudy

Erlinge D, Tsimikas S, Maeng M, et al.

Share

Articles

The aspirin heart disease prevention conundrum

Superko HR, Sninsky J, Garrett B

Share